Search Within

Lorenzo Falchi

Formats
  1. Meeting Abstract (96)
  2. Journal Article (23)
  3. Research Letter (6)
  4. Review (5)
  5. Correspondence (2)
  6. Editorial (1)
  7. Guidelines (1)
Groups
  1. Department of Medicine (134)
  2. Hematologic Malignancies, Division of (134)
  3. Center for Hematologic Malignancies (88)
  4. Lymphoma (78)
  5. Sloan Kettering Institute Postdocs (57)
  6. Survivorship Research (54)

More Groups

People
  1. Gilles Salles (66)
  2. Andrew Zelenetz (64)
  3. Maria Palomba (63)
  4. Anita Kumar (61)
  5. Ariela Noy (57)
  6. Alison Moskowitz (54)

More People

Years
  1. 2025 (8)
  2. 2024 (40)
  3. 2023 (43)
  4. 2022 (23)
  5. 2021 (14)
  6. 2020 (6)
Publications
  1. Blood (67)
  2. Journal of Clinical Oncology (11)
  3. Hematological Oncology (9)
  4. Blood Advances (5)
  5. Clinical Lymphoma, Myeloma and Leukemia (5)
  6. Leukemia and Lymphoma (5)

More Publications

Publishers
  1. American Society of Hematology (72)
  2. American Society of Clinical Oncology (11)
  3. Wiley Blackwell (9)
  4. Elsevier Inc. (8)
  5. Taylor & Francis Group (5)
  6. Ferrata Storti Foundation (4)

More Publishers

Results (134)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Subcutaneous epcoritamab with R-CHOP in previously untreated high-risk diffuse large B-cell lymphoma, including double-hit/triple-hit lymphoma: Updated results from EPCORE NHL-2
    Meeting Abstract

    Falchi, L.; Clausen, M. R.; Offner, F.; de Vos, S.; Brody, J. D.; Kim, M. L.; Snauwaert, S.; Cordoba, R.; Oki, T.; Bykhovski, I.; more...
    American Journal of Hematology (2023)

    Fulltext@MSK | Save
  • Epcoritamab + R2 regimen and responses in patients with high-risk follicular lymphoma, regardless of POD24 status
    Meeting Abstract

    Merryman, R. W.; Belada, D.; Sureda, A.; Leppä, S.; Vermaat, J. S. P.; Holte, H.; Hutchings, M.; Lugtenburg, P.; de Vos, S.; Abrisqueta, P.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Epcoritamab + R-CHOP in patients with previously untreated (1L) high-risk diffuse large B-cell lymphoma, including double-hit/triple-hit lymphoma: Updated EPCORE NHL-2 data
    Meeting Abstract

    Falchi, L.; Clausen, M. R.; Offner, F.; de Vos, S.; Brody, J.; Linton, K. M.; Snauwaert, S.; Cordoba, R.; Wu, J.; Bykhovski, I.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy
    Journal Article

    Johnson, W. T.; Ganesan, N.; Epstein-Peterson, Z. D.; Moskowitz, A. J.; Stuver, R. N.; Maccaro, C. R.; Galasso, N.; Chang, T.; Khan, N.; Aypar, U.; more...
    Blood Advances (2023)

    Fulltext@MSK | Save
  • Retrospective characterization of nodal marginal zone lymphoma
    Journal Article

    Stuver, R.; Drill, E.; Qualls, D.; Okwali, M.; Batlevi, C. L.; Caron, P. C.; Dogan, A.; Epstein-Peterson, Z. D.; Falchi, L.; Hamlin, P. A.; more...
    Blood Advances (2023)

    Fulltext@MSK | Save
  • Glofitamab monotherapy in pts with relapsed/refractory (R/R) large B-cell lymphoma (LBCL): Extended follow-up and landmark analyses from a pivotal phase II study
    Meeting Abstract

    Falchi, L.; Carlo-Stella, C.; Morschhauser, F.; Hutchings, M.; Bachy, E.; Cartron, G.; Khan, C.; Tani, M.; Martinez-Lopez, J.; Bartlett, N. L.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Epcoritamab + R (2) regimen and responses in high-risk follicular lymphoma, regardless of POD24 status
    Meeting Abstract

    Merryman, R.; Belada, D.; Sureda, A.; Leppä, S.; Vermaat, J. S. P.; Holte, H.; Hutchings, M.; Lugtenburg, P.; de Vos, S.; Abrisqueta, P.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Metabolic response rates of epcoritamab + R-CHOP in patients with previously untreated (1L) high-risk diffuse large B-cell lymphoma, including double-hit/triple-hit lymphoma: Updated EPCORE NHL-2 data
    Meeting Abstract

    Falchi, L.; Clausen, M.; Offner, F.; de Vos, S.; Brody, J.; Linton, K. M.; Snauwaert, S.; Cordoba, R.; Wu, J.; Bykhovski, I.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • CNS radiotherapy as bridging prior to CAR T‐cell therapy for hematologic malignancies
    Meeting Abstract

    Cederquist, G.; Hubbeling, H.; Tringale, K.; Shah, G.; Alarcon Tomas, A.; Shouval, R.; Hajj, C.; Fregonese, B.; Lee, J.; Dahi, P. B.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Radiotherapy as an effective bridge for chemo‐refractory or progressive secondary CNS lymphoma
    Meeting Abstract

    Cederquist, G.; Tringale, K.; Hajj, C.; Hubbeling, H.; Sarkar, R.; Ma, J.; Dreyfuss, A.; Fregonese, B.; Lee, J.; Salles, G.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save